In­ozyme brings $67M to the bank to build up its cal­ci­fi­ca­tion-fo­cused rare dis­ease pipeline

In­ozyme founder Ax­el Bolte is in­ten­si­fy­ing his faith in his rare-dis­ease up­start’s lead ex­per­i­men­tal drug by test­ing it for a sec­ond in­di­ca­tion fo­cused on dis­or­ders char­ac­ter­ized by ab­nor­mal cal­ci­fi­ca­tion. An ex­pand­ed clin­i­cal pro­gram for the drug — which is be­ing read­ied for hu­man test­ing — needs more cap­i­tal, and the biotech has raised some in a fresh $67 mil­lion round, led by Piv­otal bioVen­ture Part­ners and Sofinno­va In­vest­ments.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.